Lilly Q1 revenue $6.96B (-11%); EPS $1.49 (-29%); core biz ex-COVID +10%; guidance raised

ELI LILLY & Co

2023-Q1 EPS reported $1.49 revenue$6,960,000,000

Revenue $6.96B, down 11% YoY; ex-COVID-19 antibodies up 10% on Mounjaro, Trulicity, Verzenio, Jardiance.
Reported EPS $1.49, down 29%; non-GAAP EPS $1.62, down 38%; both include $0.10 acquired IPR&D.
2023 reported EPS guidance raised to $8.18-$8.38; non-GAAP to $8.65-$8.85 (up $0.30).
New Products (Mounjaro, Jaypirca) contributed $573.6M; Growth Products rev $4.56B (+18%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELI LILLY & Co reported First Quarter 2023 results: revenue $6,960.0, net income $1,344.9, EPS $1.49. Guidance raised.

Period: First Quarter 2023
Revenue: $6,960.0
Net income: $1,344.9
EPS: $1.49
Guidance: raised
Result: reported results

Exact text from the filing

Financial Results $ in millions, except per share data First Quarter 2023 2022 % Change Revenue $6,960.0 $7,810.0 (11)% Net Income – Reported 1,344.9 1,902.9 (29)% EPS – Reported 1.49 2.10 (29)% Net Income – Non-GAAP 1,463.9 2,372.8 (38)% EPS – Non-GAAP 1.62 2.62 (38)%

View on SEC.gov

Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-23-000160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.